High resolution computed tomography in cystic fibrosis: correlation with pulmonary function and assessment of prognostic value.
primary studies published, non RCT
Details- 1996
- Logan PM
Home intravenous antibiotic therapy vs. hospital therapy - an alternativ for patients with cystic fibrosis?.
primary studies published, non RCT
Details- 1996
- Magdorf K
Glycemic response to dietary supplements in cystic fibrosis is dependent on the carbohydrate content of the formula.
primary studies published, non RCT
Details- 1996
- Milla C
Proband and parent assistance in identifying relatives for cystic fibrosis carrier testing.
primary studies published, non RCT
Details- 1996
- Sorenson JR
Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector.
primary studies published, non RCT
Details- 1995
- Hay JG
A Phase 2, Multicenter, Randomized, Active-controlled Study to Assess the Safety and Efficacy of ANG003 at Two Different Dose Levels in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis - Not yet recruiting
primary studies published, non RCT
Details- 2026
- Anagram Therapeutics, Inc.
A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments for the Intensive Phase of Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial - Not yet recruiting
primary studies published, non RCT
Details- 2026
- The University of Queensland
The effect of compound honey syrup on clinical manifestations of chronic sinusitis in cystic fibrosis (CF) patients - Recruiting
primary studies published, non RCT
Details- 2021
A Phase 3b Open-label Study Evaluating the Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cough and Physical Activity in Cystic Fibrosis Subjects 12 Years of Age and Older Who Are Heterozygous for the F508delMutation and a Minimal Function Mutation (F/MF)
primary studies published, non RCT
Details- 2021
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Adult Participants With Cystic Fibrosis - Phase 2 - Not yet recruiting
primary studies published, non RCT
Details- 2021
- AbbVie